Although of three large randomized controlled studies, KEYNOTE-022, IMspire150, and COMBI-I for the triplet regimen of immunotherapy combined with targeted drugs in advanced melanoma patients with BRAF V600 mutations, none demonstrated meaningful improvements in OS, and all three trials reported increases in adverse events in the triple therapy group (39–41). The gene discussed is BRAF; the disease is melanoma.